$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here.
Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it breaks to the upside given the technical pattern suggesting the smart...
EVFM Evofem Biosciences has a big upcoming catalyst:
Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results!
Positive study outcomes would enable potential U.S. approval for prevention of these sexually...
NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI® for Critical COVID-19 and NRX-101 for bipolar depression with suicidality.
52 Week Range 2.38 - 48.80.
in 2020 the stock was $77.
My price target is 16.50
If this is not the time to buy this stock, then when?!
Palisade Bio, Inc. (PALI) plans to initiate a phase 3 study for accelerating the return of bowel function in the first half of 2022 and for the first patient to be enrolled in the second half of 2022.
On 2/2/2022 LADENBURG THALM/SH SH brokerage Initiated Coverage for PALI with a Buy rating and $5.00 Price Target.
Market Cap 12.841Mil
52 Week Range 0.76 -...
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees,...
MGEN has been getting hammered lately. Not one single green close in the last few weeks. Friday was the first, somewhat green close and that ain't saying much. But trading action was interesting.
"riday’s action was something much different than what the penny stock had seen during the 2 weeks prior. It was the first trading day that MGEN shares didn’t close...
FDA phase 3 failure led to a massive dump.
As we know, every reaction in the market is an over-reaction, so get in while it is cheap, or wait and see.
Maybe selling puts here could be the correct action.
Best of luck.
![GBPUSD: GBPUSD [Distribution Phase C]](https://s3.tradingview.com/z/zy6CuwUa_mid.png "GBPUSD [Distribution Phase C]")
